GAITHERSBURG, MD--(Marketwire - 03/30/11) - Noble Life Sciences, a provider of preclinical research services to the pharmaceutical and biotechnology industries, announced today the appointment of Dr. Kenneth Carter, PhD, as the company's President and Chief Executive Officer.
"I am very pleased to lead Noble Life Sciences' experienced and talented team," said Dr. Carter. "This opportunity is exceptionally exciting. The research and development of drugs and their companion diagnostics, using biomarkers to support personalized medicine, is a field in which we believe our expertise can significantly advance the development of better and more targeted medicines."
Noble Life Sciences provides preclinical experimental design and testing services and a proven biomarker validation platform used by researchers in pharmaceutical, biotechnology, and diagnostic companies as well as those in academic and government institutions. The company also offers an extensive menu of vivarium services.
Prior to joining Noble full time, Dr. Carter was a consultant to the life sciences industry and served on an interim basis as the President of Noble. Dr. Carter has played a key role in launching several biotechnology companies including co-founding NeoDiagnostix, Inc., a company recently acquired by Celgene that developed and markets a unique and highly predictive DNA biomarker-based test for cervical cancer. Dr. Carter also co-founded Avalon Pharmaceuticals, Inc. where he served as CEO for 10 years until 2009 when Avalon merged with Clinical Data, Inc. During his tenure at Avalon, the company developed a novel biomarker-based drug discovery and development engine; completed an IPO and listing on the NASDAQ market; established drug discovery programs in colon, breast, pancreatic and hematological cancers; and established partnerships with Merck, Novartis, Sanofi-Aventis, and AstraZeneca/MedImmune. Prior to that, Dr. Carter directed the gene mapping initiative at Human Genome Sciences, Inc. where he played a lead role in the discovery, cloning, and chromosomal mapping of dozens of novel human genes. Dr. Carter serves on the Advisory Council for the Center for Biotechnology Education at Johns Hopkins University where he also holds an adjunct faculty appointment.
Noble Life Sciences also announced today the appointment of Alain Cappeluti as the Chief Financial Officer. Mr. Cappeluti has more than 30 years of experience in finance and accounting for private and public companies, with more than 20 of those years spent in the biotech industry working for BioReliance, Human Genome Sciences (HGS), and CoGenesys. Mr. Cappeluti was part of the team that spun out Cogenesys from HGS in 2006 and was the CFO until the company was sold to Teva Pharmaceuticals in 2008. He also serves on the board of O-Traces, Inc., an early stage cancer diagnostics company and serves as a consultant to other life science companies.
About Noble Life Sciences:
Noble Life Sciences provides a continuum of preclinical research services including preclinical experimental design and testing, disease models, selection and validation of biomarkers for personalized medicine, and vivarium services. With deep expertise in cancer drug development, the company offers access to their top scientists and works collaboratively with researchers in pharmaceutical, biotechnology, and diagnostic companies as well as those in academic and government institutions to deliver relevant, actionable information needed to expedite preclinical research and guide clinical development. For more information about Noble Life Sciences, visit www.noblelifesci.com.
Media Contact Information